eng Oriental Scientific Publishing Company Biomedical and Pharmacology Journal 0974-6242 2026-05-08 19 2 71700 article Subhayan Sur 1 Cancer and Translational Research Centre,Dr. D. Y. Patil Biotechnology and Bioinformatics Institute, Dr. D. Y. PatilVidyapeeth (DPU), Pune, India Oral squamous cell carcinoma (OSCC) remains a major global health burden with limited therapeutic success. Advances in transcriptomic profiling have identified long non-coding RNAs (lncRNAs) as key regulators of OSCC progression and therapy resistance. This short communication summarizes recent developments in lncRNA-based therapeutic strategies identified through focused literature analysis using PubMed, Google Scholar, and ClinicalTrials.gov. Preclinical evidence from xenograft and patient-derived xenograft models demonstrates the potential of antisense oligonucleotides, RNA interference, CRISPR-based genome modulation, and exosome-mediated delivery to silence oncogenic lncRNAs or restore tumor-suppressive lncRNAs. Although clinical translation remains early, these findings highlight emerging precision therapeutic opportunities in OSCC. https://biomedpharmajournal.org/vol19no2/advancements-in-oral-cancer-therapeutics-using-long-non-coding-rnas/ Antisense Oligonucleotide (ASO) Long Non-Coding RNAs (lncRNAs) Oral Squamous Cell Carcinoma (OSCC) RNA interference (RNAi) Therapeutics